| Animal type |
|
| Rat |
11 (58) |
| Mouse |
7 (37) |
| Sheep |
1 (5) |
| Rat (n = 11) |
|
| Sprague-Dawley |
9 (82) |
| Wistar |
2 (18) |
| Mouse (n = 7) |
|
| C57Bl/6 |
7 (100) |
| Gender |
|
| Male |
3 (16) |
| Mixed |
3 (16) |
| Not reported |
13 (68) |
| Age |
|
| Fetal |
1 (5) |
| 3 days |
1 (5) |
| 7 days |
7 (37) |
| 9 days |
7 (37) |
| 10 days |
2 (11) |
| Not reported |
1 (5) |
| Mesenchymal stromal cell characteristics |
| Source |
|
| Bone marrow |
10 (53) |
| Umbilical cord |
5 (26) |
| Placenta |
1 (5) |
| Not reported |
3 (16) |
| Origin |
|
| Allogeneic |
11 (58) |
| Xenogeneic |
8 (42) |
| Dose (n = 24;>1 dose per study included) |
|
| ≤250,000 cells |
9 (37) |
| >250,000 cells—≤500,000 cells |
5 (21) |
| >500,000 cells—≤1,000,000 cells |
5 (21) |
| >1,000,000 cells |
5 (21) |
| Experimental characteristics |
| HIE model |
|
| Carotid artery occlusion + hypoxia |
15 (79) |
| Middle cerebral artery occlusion |
2 (11) |
| Umbilical cord occlusion |
1 (5) |
| Not reported |
1 (5) |
| Delivery |
|
| Intracerebral |
9 (47) |
| Intranasal |
5 (26) |
| Intravenous |
2 (11) |
| Other |
3 (16) |
| Timing after HIE injury (n = 21;>1 administration per study included) |
|
| ≤72 hours |
9 (43) |
| >72 hours |
7 (33) |
| Multiple doses |
5 (24) |
| Survival periods |
| Duration of study |
|
| ≤30 days |
11 (58) |
| >30 days—≤ 3 months |
7 (37) |
| > 1 year |
1 (5) |
| Mortality rate after HIE induction |
|
| <10% |
3 (16) |
| 10% |
6 (31) |
| >10% |
3 (16) |
| Not reported |
7 (37) |
